Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Mollard LM, Chauveau A, Boyer-Perrard F, et al. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase. Leuk Lymphoma. 2018;4:1–9.
   Google Scholar
• Odenike O. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2018;132:2339–2350.
   PubMed Web of Science ®Google Scholar
• Niscola P, Giovannini M, Scaramucci L, et al. Idiopathic thrombocytopenic purpura coexisting with polycythemia vera. Asian J Transfus Sci. 2011;2:187–188.
   Google Scholar
• Niscola P, Catalano G, Fratoni S, et al. Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis. Blood Res. 2013;48:228–230.
   PubMedGoogle Scholar
• Kajtár B, Rajnics P, Egyed M, et al. Case report: concomitant chronic lymphocytic leukaemia and cytogenetically normal de novo acute leukaemia in a patient. Ann Clin Lab Sci. 2015;45:602–606.
   PubMed Web of Science ®Google Scholar
• Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010;116:3735–3742.
   PubMed Web of Science ®Google Scholar
• Andriani A, Montanaro M, Voso MT, et al. Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Leuk Res. 2015;39:801–804.
   PubMed Web of Science ®Google Scholar
• Badar T, Kantarjian HM, Ravandi F, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015;39:950–956.
   PubMed Web of Science ®Google Scholar
• Niscola P, Abruzzese E, Trawinska MM, et al. Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation. Acta Oncol. 2017; 56:1331–1333.
   PubMed Web of Science ®Google Scholar
• Abruzzese E, Trawinska MM, Neri B, et al. Successful decitabine treatment in unfit, elderly patients with acute myeloid leukemia following chronic myeloproliferative neoplasm. Acta Haematol. 2018;1140: 231–233.
   Google Scholar
• Niscola P, Tendas A, Abruzzese E, et al. Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice. Ann Hematol. 2017;96:1591–1593.
   PubMed Web of Science ®Google Scholar
• Niscola P, Tendas A, Cupelli L, et al. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting. Acta Haematol. 2015;133:64–66.
   PubMed Web of Science ®Google Scholar
• Santini V. How I treat MDS after hypomethylating agent failure. Blood. 2019;133:521–529.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93:401–407.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus?. Blood. 2018;132:1007–1012.
   PubMed Web of Science ®Google Scholar
• Sharma P, Pollyea DA. Shutting down acute myeloid leukemia and myelodysplastic syndrome with BCL-2 family protein inhibition. Curr Hematol Malig Rep. 2018;13:256–264.
   PubMed Web of Science ®Google Scholar
• Leverson JD, Sampath D, Souers AJ, et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov. 2017;7:1376–1393.
   PubMed Web of Science ®Google Scholar
• Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362–375.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106–1117.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Cai T, DiNardo CD, et al. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019;9:4.
   PubMed Web of Science ®Google Scholar
• Tabarroki A, Saunthararajah Y, Visconte V, et al. Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. Leuk Lymphoma. 2015;56:497–499.
   PubMed Web of Science ®Google Scholar